Here, we investigate the antimyeloma potential of two-drug combination comprising bortezomib and STING agonist in transplantable Vĸ*MYC model, a well-established syngeneic murine immunocompetent model for preclinical studies of drug efficacy in MM [14]. The gene discussed is MYC; the disease is Miyoshi myopathy.